Market Closed -
Other stock markets
|
Pre-market 06:49:17 | |||
10.80 EUR | +2.96% |
|
10.68 | -1.11% |
07-08 | European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading | MT |
07-03 | Grifols, S.A., 2024 Earnings Call, Feb 26, 2025 |
Business description: Grifols, S.A.
- products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Number of employees: 23,800
Sales by Activity: Grifols, S.A.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Biopharma | 4.24B | 3.81B | 5.01B | 5.56B | 6.14B |
Bio Supplies | 224M | 226M | 146M | 160M | 216M |
Diagnostic | 776M | 779M | 671M | 670M | 645M |
Others | 31.99M | 39.62M | 250M | 203M | 209M |
Intersegments | -53.11M | -67.55M | -8.95M | - | - |
Hospital | 119M | 141M | - | - | - |
Geographical breakdown of sales: Grifols, S.A.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States + Canada | 3.6B | 3.15B | 3.86B | 3.9B | 4.09B |
Rest of the World | 906M | 872M | 1.18B | 1.44B | 1.58B |
Rest of European Union | 495M | 544M | 712M | 893M | 1.12B |
Spain | 339M | 362M | 321M | 363M | 423M |
Executive Committee: Grifols, S.A.
Manager | Title | Age | Since |
---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 56 | 31/03/2024 |
Jörg Schüttrumpf
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/08/2024 |
Director of Finance/CFO | 62 | 31/12/1995 | |
Comptroller/Controller/Auditor | 46 | 31/12/2015 | |
Lafmin Morgan
PRN | Corporate Officer/Principal | 61 | 30/06/2018 |
Composition of the Board of Directors: Grifols, S.A.
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 12/04/2000 | |
Director/Board Member | 62 | 23/05/2015 | |
Director/Board Member | 49 | 29/05/2016 | |
Director/Board Member | 60 | 23/05/2019 | |
Director/Board Member | 57 | 09/06/2022 | |
Director/Board Member | 48 | 09/06/2022 | |
Albert Coma-Cros
BRD | Director/Board Member | 47 | 18/12/2023 |
Director/Board Member | 60 | 28/05/2015 | |
Nacho Abia
BRD | Director/Board Member | 56 | 25/02/2024 |
Chairman | 61 | 04/06/2025 |
Holdings: Grifols, S.A.
Name | Equities | % | Valuation |
---|---|---|---|
437,069,656 | 6.49% | 419,044,903 $ |
Company details: Grifols, S.A.
Grifols SA
Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan
08174, Barcelona
+34 935 712 200
http://www.grifols.com
Group companies: Grifols, S.A.
Name | Category and Sector |
---|---|
Gri-Cel SA
![]() Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA is a Spanish company that provides investment services. The company is based in Barcelona, Spain. The CEO of the company is Dirk Büscher. |
Financial Conglomerates
|
Grifols India Healthcare Pvt Ltd. | |
Squadron Reinsurance DAC
![]() Squadron Reinsurance DAC Multi-Line InsuranceFinance Part of Grifols SA, Squadron Reinsurance DAC is an Irish company that provides reinsurance services. The company is based in Dublin, Ireland. |
Multi-Line Insurance
|
Biopharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+2.96% | +4.35% | +20.13% | -36.34% | 7.7B | ||
-0.98% | +1.53% | -18.45% | -15.47% | 77.69B | ||
+1.79% | +2.40% | -47.94% | -11.88% | 57.88B | ||
-1.55% | +2.12% | +26.15% | +23.99% | 52.56B | ||
+0.12% | +1.89% | +19.12% | +100.12% | 37.85B | ||
+3.33% | +3.38% | -41.04% | -38.55% | 19.7B | ||
-0.67% | +3.15% | +116.40% | +122.28% | 17.93B | ||
+0.48% | +12.63% | +50.18% | +694.31% | 16.32B | ||
-0.04% | -.--% | +84.28% | +129.06% | 14.02B | ||
+0.59% | -1.54% | +16.33% | -15.92% | 13.1B | ||
Average | +0.01% | +2.57% | +22.52% | +95.16% | 31.48B | |
Weighted average by Cap. | -0.32% | +2.45% | +4.89% | +54.80% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GRF Stock
- Company Grifols, S.A.
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition